Clinical trialNCT07227311RecruitingPhase 2Interventional

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

SponsorGlaxoSmithKlineEnrollment200Multiple Myeloma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment. The main goal is to find out if the study drug, belantamab mafodotin, given less often (on an extended schedule) with other cancer medicines, can still treat the cancer effectively while causing fewer side effects, especially those affecting the eyes. The study will also look at how well the treatment works overall and how safe it is when administered to the participants.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

51 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

France

Gsk Investigational Site
Dunkirk, Nord, France
Helene Demarquette
Recruiting
Gsk Investigational Site
Nantes, France
Cyrille Touzeau
Recruiting
Gsk Investigational Site
Paris, France
Zoe Van De Wyngaert
Recruiting
Gsk Investigational Site
Paris, France
Alexis Talbot
Recruiting
Gsk Investigational Site
Paris, France
Laurent Garderet
Recruiting
Gsk Investigational Site
Saint-Etienne, France
Emilie Chalayer
Recruiting

Germany

Gsk Investigational Site
Frankfurt, Germany
Moritz Bewarder
Recruiting
Gsk Investigational Site
Hamburg, Germany
Hans Salwender
Recruiting
Gsk Investigational Site
Karlsruhe, Germany
Stefanie Lemnitz
Recruiting
Gsk Investigational Site
Koblenz, Germany
Andreas Guenther
Recruiting
Gsk Investigational Site
München, Germany
Marcus Hentrich
Recruiting

Greece

Gsk Investigational Site
Athens, Greece
SOSANA DELIMPASI
Recruiting
Gsk Investigational Site
Athens, Greece
Meletios Athanasios Dimopoulos
Recruiting
Gsk Investigational Site
Thessaloniki, Greece
Michail Iskas
Recruiting

Japan

Gsk Investigational Site
Aichi, Japan
Shinsuke Iida
Recruiting
Gsk Investigational Site
Chiba, Japan
Kaichi Nishiwaki
Recruiting
Gsk Investigational Site
Ehime, Japan
Tomoaki Fujisaki
Recruiting
Gsk Investigational Site
Fukushima, Japan
Takayuki Ikezoe
Recruiting
Gsk Investigational Site
Gunma, Japan
Hiroshi Handa
Recruiting
Gsk Investigational Site
Hokkaido, Japan
Masayoshi Kobune
Recruiting
Gsk Investigational Site
Ishikawa, Japan
Hiroyuki Takamatsu
Recruiting
Gsk Investigational Site
Numakunai, Japan
Shigeki Ito
Recruiting
Gsk Investigational Site
Okayama, Japan
Kazutaka Sunami
Recruiting
Gsk Investigational Site
Osaka, Japan
Shinya Rai
Recruiting
Gsk Investigational Site
Sendai, Japan
TORU IZUMI
Recruiting
Gsk Investigational Site
Tokyo, Japan
Kazuhito Suzuki
Recruiting
Gsk Investigational Site
Yamanashi, Japan
Keita Kirito
Recruiting

Netherlands

Gsk Investigational Site
Amersfoort, Netherlands
Josien Regelink
Recruiting
Gsk Investigational Site
Hoofddorp, Netherlands
Aart Beeker
Recruiting
Gsk Investigational Site
The Hague, Netherlands
Paula F. Ypma
Recruiting

South Korea

Gsk Investigational Site
Ulsan, South Korea
Jae-Cheol Jo
Recruiting

Spain

Gsk Investigational Site
Jerez de la Frontera, Andalusia, Spain
Sebastian Garzon Lopez
Recruiting
Gsk Investigational Site
Badalona, Spain
Albert Oriol
Recruiting
Gsk Investigational Site
Córdoba, Spain
Miguel Ángel Álvarez Rivas
Recruiting
Gsk Investigational Site
Gijón, Spain
Esther González Garcia
Recruiting
Gsk Investigational Site
Madrid, Spain
Joaquin Martinez Lopez
Recruiting
Gsk Investigational Site
Madrid, Spain
Arancha Alonso
Recruiting
Gsk Investigational Site
Málaga, Spain
RICARDA GARCIA SANCHEZ
Recruiting
Gsk Investigational Site
Salamanca, Spain
Maria Victoria Mateos Manteca
Recruiting
Gsk Investigational Site
Vitoria-Gasteiz, Spain
Xabier Gutierrez Lopez de Ocariz
Recruiting

11 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Belantamab mafodotin →Bortezomib →Carfilzomib →Dexamethasone →Pomalidomide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Apr 2026
Primary completion: 30 Aug 2030
Completion: 30 Aug 2030
Last update posted: 24 Jul 2026
Registered enrollment: 200
Registry id: NCT07227311

Cross-registrations

EU-CTR / CTIS (EudraCT)2025-523117-28-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.